

Leukaemia Section

Short Communication

inv(3)(p12q26)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: June 2007

Online updated version: <http://AtlasGeneticsOncology.org/Anomalies/inv3p12q26ID1275.html>

DOI: 10.4267/2042/38506

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

Disease

Chronic myelogenous leukaemia with t(9;22)(q34;q11).

Epidemiology

Only one case to date, a 74 year old female patient.

Prognosis

No data.

Cytogenetics

Cytogenetics, morphological

Anomaly accompanying the t(9;22)(q34;q11).

Genes involved and Proteins

Note: The partner of EVI1 is yet unknown.

EVI1

Location: 3q26.2

Protein

Transcription factor; EVI1 targets include: GATA2, ZBTB16 /PLZF, ZFPM2/FOG2, JNK and the PI3K/AKT pathway. Role in cell cycle progression, likely to be cell-type dependant; antiapoptotic factor; involved in neuronal development organogenesis; role in hematopoietic differentiation.

References

Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, Hagemeijer A, Speleman F. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. *Genes Chromosomes Cancer* 2006;45:349-356.

Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. *Gene* 2007 Jul 15;396(2):346-57.

This article should be referenced as such:

Huret JL. inv(3)(p12q26). *Atlas Genet Cytogenet Oncol Haematol.*2008;12(2):161.
